Dr. Stephen D. Grubb, MD
Family Medicine (Family Medicine Physician)
3600 Sea Mountain Higway, Suite C
Little River, SC 29566
Who else practices at this address →
Horry County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (1975)
- Years since graduation
- 51
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 482
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1975Medical school: Washington University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
SC license 7841 · NC license 22475
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- McLeod Loris Hospital Loris, SC
- Grand Strand Regional Medical Center Myrtle Beach, SC
- Columbus Regional Healthcare System Whiteville, NC
Medical groups
- Sc House Calls Inc (432 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 482
- Services billed
- 14,695
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 1,563 | 568 |
| Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | 1,487 | 314 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 1,154 | 430 |
| Established patient office or other outpatient visit, 30-39 minutes | 881 | 394 |
| Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | 571 | 320 |
| Automated urinalysis test | 245 | 202 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 230 | 230 |
| Advance care planning, first 30 minutes | 219 | 216 |
| Hemoglobin a1c level | 128 | 90 |
| Blood glucose (sugar) test performed by hand-held instrument | 117 | 75 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Little River, SC | 385 |
| Amlodipine Besylate Other prescribers in Little River, SC | 356 |
| Atorvastatin Calcium Other prescribers in Little River, SC | 343 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Little River, SC | 288 |
| Simvastatin Other prescribers in Little River, SC | 286 |
| Gabapentin Other prescribers in Little River, SC | 283 |
| Omeprazole Other prescribers in Little River, SC | 269 |
| Levothyroxine Sodium Other prescribers in Little River, SC | 259 |
| Losartan Potassium Other prescribers in Little River, SC | 258 |
| Rosuvastatin Calcium Other prescribers in Little River, SC | 256 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 68 payments worth $1,483 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $224 |
|---|---|
| Novo Nordisk Inc | $206 |
| Lilly USA, LLC | $202 |
| GlaxoSmithKline, LLC. | $182 |
| Amgen Inc. | $171 |
| AbbVie Inc. | $161 |
| Medtronic, Inc. | $75.84 |
| Novartis Pharmaceuticals Corporation | $35.90 |
| Food and Beverage | $1,483 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $1,133,097 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A phase 3 placebocontrolled doubleblinded randomized study to evaluate the efficacy safety and tolerability of a clostridioides difficile vaccine in adults 65 years of age and older
Pfizer Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - A phase 3 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of a combined modified rna vaccine candidate against COVID19 and influenza in healthy individuals
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.